Alembic Pharma reported a 48% increase in net profit to Rs 180 crore for the third quarter of 2023, thanks to strong sales in both domestic and export markets. Net sales increased by 8%, reaching Rs 1,631 crore. The India branded business saw improvement, while the speciality and animal health segments performed well and the acute segment did reasonably well despite challenging market conditions.